Enhanced cGAS-STING-dependent interferon signaling associated with mutations in ATAD3A
Alice Lepelley,Erika Della Mina,Erika Van Nieuwenhove,Lise Waumans,Sylvie Fraitag,Gillian I Rice,Ashish Dhir,Marie-Louise Frémond,Mathieu P Rodero,Luis Seabra,Edwin Carter,Christine Bodemer,Daniela Buhas,Bert Callewaert,Pascale de Lonlay,Lien De Somer,David A Dyment,Fran Faes,Lucy Grove,Simon Holden,Marie Hully,Manju A Kurian,Hugh J McMillan,Kristin Suetens,Henna Tyynismaa,Stéphanie Chhun,Timothy Wai,Carine Wouters,Brigitte Bader-Meunier,Yanick J Crow
DOI: https://doi.org/10.1084/jem.20201560
2021-10-04
Abstract:Mitochondrial DNA (mtDNA) has been suggested to drive immune system activation, but the induction of interferon signaling by mtDNA has not been demonstrated in a Mendelian mitochondrial disease. We initially ascertained two patients, one with a purely neurological phenotype and one with features suggestive of systemic sclerosis in a syndromic context, and found them both to demonstrate enhanced interferon-stimulated gene (ISG) expression in blood. We determined each to harbor a previously described de novo dominant-negative heterozygous mutation in ATAD3A, encoding ATPase family AAA domain-containing protein 3A (ATAD3A). We identified five further patients with mutations in ATAD3A and recorded up-regulated ISG expression and interferon α protein in four of them. Knockdown of ATAD3A in THP-1 cells resulted in increased interferon signaling, mediated by cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING). Enhanced interferon signaling was abrogated in THP-1 cells and patient fibroblasts depleted of mtDNA. Thus, mutations in the mitochondrial membrane protein ATAD3A define a novel type I interferonopathy.